💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Gefitinib

CHEMBL939 Phase 4 Одобрено Small molecule
Half-Life
48 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
446.9 g/mol
LogP
4.1
Phase
4

This oral medication blocks the epidermal growth factor receptor (EGFR), which is mutated and overactive in certain non-small cell lung cancers, stopping cancer cells from receiving growth signals. It is used as a targeted therapy for NSCLC with specific EGFR mutations.

Молекулярная масса

446,9000 g/mol

LogP

4,10

TPSA

68,70 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Классы препаратов

L — L - Antineoplastic and Immunomodulating Agents

Механизм действия

Selective reversible inhibitor of EGFR tyrosine kinase.

Pharmacokinetics (PK)

Half-Life 48 hours

Pharmacodynamics (PD)

Механизм

Selective reversible inhibitor of EGFR tyrosine kinase.

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1

                

                

                
                

                    
InChI

                    
InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H24ClFN4O3

                    

                    
                    

                        
HBD / HBA

                        
1 / 8

                    

                    
                    

                        
Вращаемые Связи

                        
8

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
31

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
This oral medication blocks the epidermal growth factor receptor (EGFR), which is mutated and overactive in certain non-small cell lung cancers, stopping cancer cells from receiving growth signals. It is used as a targeted therapy for NSCLC with specific EGFR mutations.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective reversible inhibitor of EGFR tyrosine kinase.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Gefitinib: Half-life: 48 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Gefitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Methotrexate
                            Small molecule
                        
                        
                        
                            Tamoxifen
                            Small molecule
                        
                        
                        
                            Cyclosporine
                            Protein
                        
                        
                        
                            Tacrolimus
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL939.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 123631.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.